Serum brain-derived neurotrophic factor (BDNF) as predictors of childhood neuroblastoma relapse

• Published in: BMC cancer Vol. 23; no. 1; pp. 670 - 9
• Main Authors: Xiong, Xilin, Zeng, Meiling, Peng, Xiaomin, Feng, Chuchu, Li, Chunmou, Weng, Wenjun, Li, Yang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.07.2023; BioMed Central; BMC
• Subjects: Age; Analysis; Antibodies; BDNF; Brain-derived neurotrophic factor; Cancer; Care and treatment; Chemotherapy; Childhood; Children; Clinical trials; Development and progression; Enzyme-linked immunosorbent assay; Enzymes; Health aspects; Immunoassay; Immunotherapy; Kinases; Males; Medical prognosis; Medical research; Medicine, Experimental; Neonates; Nervous system; Neuroblastoma; Normal distribution; Patient outcomes; Patients; Pediatrics; Radiation therapy; Relapse; Remission; Software; Statistical analysis; Stem cells; TrkB receptors; Tumors; Umbilical cord; China; Canada; BDNF; Relapse; Neuroblastoma
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-11159-9

Neuroblastoma (NB) is a childhood malignant tumor,50% of high-risk NB children still have recurrence, and the long-term survival rate is very low. NB tumors expressing high levels of BDNF/TrkB are associated with poor survival outcomes.In this study, we show that the trends of serum concentration of BDNF at different growth stages after birth, and explore the relationship with NB replase. In experiment 1, 87 subjects were enrolled and divided into four groups, neonates group、 children group、adults group and NB patients. The distribution of serum concentration of BDNF by ELISA. In experiment 2, we studied BDNF in stage 4 NB patients to determine their frequency, correlation with clinical parameters, and prognostic impact. First, we identified that serum BDNF concentration decreased from the newborn to childhood in healthy subjects, while it was relatively high in children(age > 1 year) with NB. In the second phase our studies showed no significant increase in serum BDNF concentration in these NB patients, with adverse pathologic features, large tumor maximum diameter, and MYCN amplification. After comprehensive treatment, levels of BDNF gradually increased in children with recurrence and decreased in the remission group. High serum BDNF concentration was associated with relapse. Of 21 stage 4 neuroblastoma patients, adopted a comprehensive treatment approach including ATO-basic modified chemotherapy, traditional radiotherapy,stem cell transplatation and immunotherapy. 76% of alive patients having > 3 years follow-up. The aim is to show that BDNF is a predictor of recurrence risk of NB.